Therapeutic potential of plasminogen activator inhibitor-1 inhibitors.
Plasminogen activator inhibitor-1 (PAI-1) is the major physiological inhibitor of fibrinolysis and regulates cell migration and fibrosis. Preclinical studies using genetically altered mice and biological or small molecule inhibitors have elucidated a role for PAI-1 in the pathogenesis of thrombosis, vascular remodeling, renal injury, and initiation of diabetes. Inhibition of PAI-1 is a potential therapeutic strategy in these diseases.
Brown
Nancy J
NJ
536 Robinson Research Building, Vanderbilt University Medical Center, Nashville, TN 37232-6602, USA. nancy.j.brown@vanderbilt.edu
D000818:Animals; D050197:Atherosclerosis / Q000188:drug therapy* / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D007210:Indoleacetic Acids / Q000494:pharmacology*; D007674:Kidney Diseases / Q000188:drug therapy / Q000378:metabolism; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism*; D011658:Pulmonary Fibrosis / Q000188:drug therapy / Q000378:metabolism; D013927:Thrombosis / Q000188:drug therapy* / Q000378:metabolism
D007210:Indoleacetic Acids; D017395:Plasminogen Activator Inhibitor 1; C488103:tiplaxtinin